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Abstract
Aims: To examine the prevalence of former heroin dependence (FHA) in Alcohol Use Disorder
(AUD) patients; to compare the clinical characteristics of FHA-AUD patients versus AUD patients
without any past use of heroin at alcohol treatment entry; to document the heroin dependence his-
tory of FHA-AUD patients, and review treatment strategies for this group.
Methods: Retrospective case review of 448 consecutive AUD patients.
Results: The annual entry of FHA-AUD showed stability over the study period of 3 years overall 60/
448 (13.3%). FHA-AUD patients showed higher concomitant use of cocaine, benzodiazepines, canna-
bis and hallucinogens than other heroin addicts. They consumed higher amounts of alcohol at the
beginning of their alcohol dependence history, and reached a high maximum level of alcohol con-
sumption, than other AUD patients, and tended to havemore physical disorders. Themost important
signals of FHA-AUD were polyabuse and older age at the time of presentation. FHA-AUD patients
tended to have had a severe pattern of heroin dependence associatedwith inadequate agonist opiate
treatment.
Conclusions: The prevalence of FHA-AUD patients is not negligible. This may relate to previous in-
adequate treatment of heroin addiction contributing to the development of severe AUD. For these
patients we propose a reconsideration of ‘soft’ (low dose) agonist opiate treatment.
INTRODUCTION
Opioid agonist treatment (AOT) is an effective programme for the
treatment of heroin dependence (Gronbladh et al., 1990; Giacomuzzi
et al., 2003; Mattick et al., 2003, 2008, 2009; Gibson et al., 2008). It
should, however, be noted that the magnitude of the gains achieved
through AOT can be strongly influenced by how treatment is delivered
(Benyamina and Stöver, 2012; Dale-Perera et al., 2012; Fischer et al.,
2012). To achieve the best results it is critical to optimize the AOT.
Vincent P. Dole, together with Marie Nyswander and Mary Jeanne
Kreek, clarified how to optimize treatment (Dole et al., 1966), and
the treatment has survived challenges from professional sceptics, ideo-
logically hostile agencies, competitive modalities, and even from well-
intentioned clinicians in methadone programmes who have prescribed
inadequate doses of the medication (Dole, 1999). No matter how
much time has gone by, we still need evidence to prove how important
it is to optimize treatment. Successful outcomes are achieved when
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patients take adequate doses and stay in treatment over the long term
(Dole and Joseph, 1978; Lowinson et al., 1992; Dole, 1994; Kritz
et al., 2009). Indeed, higher doses of agonist opioids are more effective
than lower ones in reducing illicit opioid use (Schottenfeld et al., 1997;
Maxwell and Shinderman, 1999) and, when taking higher doses, pa-
tients tend to stay in treatment longer (Johnson et al., 2000). That is
true, nomatter whether it is methadone or buprenorphine that is being
considered (Farre et al., 2002).
Although the best techniques for optimizing AOT are now known,
they are not always applied (Benyamina and Stöver, 2012; Dale-Perera
et al., 2012; Fischer and Stöver, 2012; Fischer et al., 2012; Goulão and
Stöver, 2012; Stöver, 2012); when this happens treatment outcomes
tend toworsen, and extreme attention should be paid to the possibility
of subsequent use of sedative drugs such as alcohol and benzodiaze-
pines (Mitcheson et al., 1970; Maremmani and Shinderman, 1999;
Lubrano et al., 2002).
Increases in alcohol consumption during AOT programmes have
been observed alongside dwindling heroin use, suggesting a negative
correlation between the two, at least in programmes that employ
lower dosages of methadone (Green et al., 1978; Anglin et al.,
1989; Maremmani and Shinderman, 1999; Maremmani et al.,
2007; Stenbacka et al., 2007). Similar observations can be applied
to benzodiazepine use (Maremmani and Shinderman, 1999; Vogel
et al., 2013).
There is growing evidence that alcohol use is a common problem
among people who use heroin and other illicit opiates (McCusker,
2001)—in other words, not only among former heroin-dependent pa-
tients (Ryder et al., 2009). The close linkage between these two sub-
stances has been well documented (Green et al., 1978). A history of
exposure to opiates and subsequent opiate use disorder is a frequent
background in subjects who apply for alcohol abuse treatment. The
maximum levels of alcohol consumption seem to rise as heroin use
dwindles, in some cases to nothing; this highlights a predictable shift
from regular opiate abuse to regular heavy alcohol use (Ceccanti and
Vitali, 2009); one should bear in mind the tendency to use alcohol as a
substitute for heroin (Lehman et al., 1990). In addicts’ natural envir-
onment, before any therapeutic setting has been established, alcohol
consumption may compensate for the lack of available heroin (due
to poverty, somatic impairment or temporary supply shortages), so be-
coming a commonmeans of self-handling in a situation of opiate crav-
ing (Noble et al., 2002). This can also happen when heroin-dependent
patients are prematurely removed from agonist opioid medications,
which directly favours, or fail to counter, a switching evolution of her-
oin dependence towards alcoholism, probably to obtain relief from
symptoms of narcotic craving without relapsing into the use of heroin
(Bickel et al., 1987; Ottomanelli, 1999). Conversely, if alcohol-
abusing heroin-dependent patients are prompted to take action by
entering methadone treatment, that may forestall their alcohol con-
sumption in the short term, so indicating a rapid direct action of opi-
oid agonism on alcohol craving in this population (Caputo et al.,
2002).
The purpose of the present paper is 3-fold:
• First, to analyse the prevalence of former heroin addiction in AUD
patients requesting treatment for Alcohol Use Disorders (AUD) at
Alcohol Units (FHA-Alcoholic patients).
• Second, to compare the clinical characteristics of former heroin-
dependent AUD patients and AUD patients without any past use
of heroin (NFHA-Alcoholic patients) at alcohol treatment entry.
• Third, to describe the heroin dependence history and previous
treatment of these patients.
METHODS
A comparative cohort study was designed to compare the demograph-
ic, clinical and diagnostic characteristics of AUD patients with and
without past heroin use. All patients included in the study signed an
informed consent form. The competent ethics committees, in accord-
ance with internationally accepted criteria for ethical research,
approved both the consent form and the experimental procedures.
Since 2004, the Centre for the Assessment and Treatment of
Alcohol-Related Pathology, La Sapienza University, at the Umberto
I University Hospital in Rome has been using a clinical protocol that
comprises a detoxification unit, which may be followed by a long-term
outpatient psychopharmacological approach to prevent relapses. Pa-
tients displaying major psychomotor excitement, aggressive, and sui-
cidal behaviour, or major psychotic symptoms were referred to the
local psychiatric inpatient unit. For these patients, the initiation of
the outpatient treatment was postponed.
We considered all consecutive AUD patients, according to DSM-IV
TRcriteria, who had been referred for treatment to the outpatient clinic,
during the years 2004–2007. Previous studies had been performed with
this sample (Ceccanti and Vitali, 2009; Pacini et al., 2010b).
All patients were evaluated after the resolution of acutewithdrawal
to avoid, in the diagnostic process, possible interferences arising from
the acute phase of their illness.
Assessment
Alcoholism-related information was collected by means of the Drug
Addiction History Questionnaire (DAH-Q) (Maremmani and Castro-
giovanni, 1989)—alcohol version, administered by a psychiatrist. The
DAH-Q is a multiscale questionnaire comprising these categories:
sociodemographic information, physical health, mental health, sub-
stance abuse, treatment history, social adjustment and environmental
factors. DAH-Q was specifically designed to register information re-
garding illicit drug users. For patients who were also alcoholics, we
further registered the number of alcohol units per day at evaluation
time and maximum lifetime.
Psychiatric Diagnostic Evaluation Structured Clinical Interview for
DSM-IV Axis I Disorders (SCID-I), Clinician Version was adminis-
tered. It is specifically adapted for Axis I structured clinical interview-
ing for use in clinical settings (First et al., 1997) and covers the
DSM-IV diagnoses most commonly seen by clinicians. According to
our criteria, there was a ‘dual diagnosis’when we determined the pres-
ence of both alcohol dependence and an autonomous psychiatric dis-
order. Autonomy of additional psychiatric syndromes was assessed
with reference to an independent course with respect to substance
abuse, and the specificity of symptoms with respect to expected intoxi-
cation or withdrawal pictures.
Regarding bipolar spectrum diagnoses, both the history of earlier
hypomanic episodes, and temperamental characteristics were explored
using the criteria listed in the SID, the Semi-structured Interview for De-
pression (Cassano et al., 1989). All information was gathered from the
patient and at least one close relative (usually parents, siblings); in add-
ition, all available clinical records were carefully examined. Inquiries on
temperamental attributes focused on the habitual self of the patient dur-
ing periods free of affective episodes—the sources being patients and
their significant others (Akiskal and Mallya, 1987).
Statistical analysis
We compared FHA-AUD patients and all AUD patients with reference
to: demographic data, physical health, psychiatric diagnoses,
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substance abuse and social adjustment. The variables that showed
statistically significant differences (P < 0.05) for an association with
past heroin use were included in separate logistic backward regression
analyses comprising the issue of belonging to the FHA-AUD patients
group as a dependent variable. Then we described FHA-AUD patients
by reviewing their heroin dependence history and treatment history.
Statistical analyses were carried out using the SPSS package. As this
is an exploratory study, statistical tests were considered significant at
the P < 0.05 level.
RESULTS
The study included 448 patients of whom 338 (75.4%)were male, and
mean age was 44 years (SD = 9; min 19 max 74). Most were single
(155, 34.6%), had had <8 years of education (230, 51.3%) and
were employed (344, 76.8%). Sixty AUD patients were former heroin-
dependent patients (FHA-AUD patients). Of these, 50 (83.3%) were
males, of mean age 43 ± 6 years. They were characterized by the con-
comitant use of cocaine (75.0%), benzodiazepines (25.9%) and can-
nabinoids (65.0%). The other 388 AUD patients (mean age 44 ± 1
years) had never used heroin; 228 (74.2%) were male.
The prevalence of FHA-AUD patients at this clinic was 15/99
(15.1%) in 2004; there were 22/159 (13.8%) new cases in 2005,
and 16/151 (10.5%) in 2006. Reviewed cumulatively in 2007, cases
of this type totalled 60/448 (13.3%).
Table 1 compares FHA-AUD patients and NFHA-AUD patients
on demographic characteristics, psychiatric comorbidity, social adjust-
ment and drug addiction history. No differences emerged as to age
(P = 0.580), gender (P = 0.127), civil status (P = 0.289), unemployment
rates (P = 0.526), level of education (P = 0.082) or living situation (P =
0.219). No differences were found between the two groups regarding
age at first use of alcohol (P = 0.452), and at first misuse of alcohol (P =
0.806), duration of drinking habit (P = 0.882) and the duration in years
of alcoholism (P = 0.506). No differences emerged, either, for the
presence of a psychiatric diagnosis (P = 0.533) or problematic social
adjustment (P = 0.364). FHA-AUD patients showed a higher concomi-
tant use of cocaine (P = 0.000), benzodiazepines (P = 0.000), cannabis
(P = 0.000) and hallucinogens (P = 0.011). They consumed a higher
amount of alcohol at the beginning of their dependence history (P =
0.003), and reach a higher maximum level of alcohol consumption
(P = 0.016). There is a trend towards more severe physical complica-
tions in FHA-alcoholic patients (P = 0.056).
Table 2 shows the most significant correlates of former heroin use
in AUD patients. Concomitant use of cocaine and cannabis is the
strongest correlate of being a former heroin alcoholic. Moreover,
being older at the time of present treatment is positively correlated
with past heroin use. In other words, former heroin AUD patients
are rather typical of the older generation of AUD patients, showing
a concomitant use of cocaine and cannabinoids (chi-square = 75.01;
df = 3; P < 0.001).
Table 3 shows the heroin dependence history of 60 FHA-AUD pa-
tients at treatment entry. FHA-AUD patients reported their age at first
continuous use of heroin to be 22.12 ± 8.2. Of these 60 patients,
88.3% reached the ‘revolving door phase’ (Stage 3) and showed a de-
pendence length of 9.38 years ± 5.5. The development of addiction
may be considered to consist of three stages: 1-acute (immediate)
drug effects (Honeymoon Stage); 2-transition from recreational use
to patterns of use consistent with addiction (Increasing Dose Stage);
Table 1. Univariate association between past use of heroin in AUD patients and sociodemographic characteristics, psychiatric comorbidity,
social adjustment and drug addiction history
FHA-AUD patients
N = 60
NFHA-AUD patients
N = 388
Chi/T P
Age (mean ± SD) 43.38 ± 6.3 44.13 ± 10 0.55 0.580
Sex (male) 50 (83.3) 228 (74.2) 2.32 0.127
Civil status (single) 37 (64.9) 197 (57.4) 1.12 0.289
Unemployed 29 (48.3) 157 (40.5) 2.23 0.526
High educational level (>8 years) 29 (48.3) 142 (36.6) 3.03 0.082
Living alone 21 (35.0) 106 (27.3) 1.50 0.219
Concomitant use of Cocaine 45 (75.0) 99 (25.5) 58.34 0.000
Concomitant use of BZD 15 (25.9) 21 (5.6) 27.37 0.000
Concomitant use of THC 39 (65.0) 67 (17.3) 65.30 0.000
Concomitant use of hallucinogens 4 (7.0) 6 (1.6) 6.44 0.011
Diagnosis
Chronic psychosis 1 (1.7) 10 (2.6)
Recurrent depression 1 (1.7) 23 (5.9)
Bipolar spectrum 15 (25.0) 111 (28.6)
Anxiety disorders 2 (3.3) 17 (4.4)
Absence of dual diagnosis 41 (68.3) 227 (58.5) 3.15 0.533
Age at first use of alcohol 15.17 ± 4.8 15.70 ± 5.1 0.75 0.452
Age at first misuse of alcohol 24.27 ± 6.4 24.02 ± 7.2 −0.24 0.806
Drinking duration 28.22 ± 8.2 28.44 ± 10.6 0.14 0.882
Alcoholism duration 19.15 ± 8.6 20.12 ± 10.7 0.66 0.506
Initial alcohol Units/daily 9.78 ± 9.1 7.02 ± 7.5 −2.95a 0.003
Max alcohol Units/daily 25.13 ± 11.6 21.55 ± 10.1 −2.40a 0.016
Severe physical complications 16 (26.7) 64 (16.5) 3.66 0.056
Problematic social adjustment 28 (46.7) 157 (40.5) 0.82 0.364
aMann–Whitney z-test.
BZD, benzodiazepines; THC, cannabinoids.
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and 3-end-stage addiction, which is characterized by an overwhelming
desire to obtain the drug, a diminished ability to control drug-seeking
and reduced pleasure from biological rewards (Revolving Door Stage)
(Kalivas and Volkow, 2005).
The mean age for stopping heroin usewas 34.09 ± 7.2; 60% stayed
free of heroin for at least 2 years. Considering their treatment history,
FHA-AUD patients set their age at the moment when alcohol treat-
ment was requested at 43.38 ± 6.3, corresponding to a mean of
about 9 years after they had stopped heroin use. In the past, only
30.5% had been enrolled in an opioid agonist treatment and those
had spent a mean of 5.30 ± 4.0 years in AOT with only 56.6% reach-
ing ‘blocking dosages’ of opioid medications. They were 33.92 ± 8.1
years old at their last AOT.
According to Dole and Nyswander’s theory the methadone block-
ing dosage is the dosage that blocks the patient’s abnormal reactions to
heroin and permits him/her to live as a normal citizen in the commu-
nity. Generally this dosage is above 60 mg/day—in our experience at
least 80 mg/day of methadone or 16 mg/day of buprenorphine (Dole
et al., 1966; Pacini et al., 2010a; Maremmani et al., 2011).
DISCUSSION
During the 2004–2007 period, the prevalence of FHA-AUD patients
varied between 10.5 and 15.1%.
FHA-AUD patients show a greater concomitant use of cocaine,
benzodiazepines, cannabinoid and hallucinogens than NFHA-AUD
patients. Their alcohol use is characterized by a higher number of al-
cohol units/daily at the beginning of AUD. FHA-AUD patients show a
concomitant use of cocaine and cannabinoids. They are distinguished
by a significant heroin dependence history. Only 30.5% of FHA had
enrolled in an AOT, and of these patients only 56.6% reached block-
ing dosages.
Being older and abusing cocaine and cannabinoids are correlates
of past heroin use. Being older is not surprising because, if alcohol is
considered as a negative outcome or a consequence of incorrect opioid
treatment, we expected that time will elapse before patients request
treatment for alcohol-related problems.
Moreover, the addiction history of these patients is complicated by
polyabuse. The presence of polyabuse, especially in heroin-addicted
patients, can reflect an unsatisfactory treatment outcome (Lubrano
et al., 2002; Maremmani et al., 2007; Somers and O’Connor,
2012), polyabuse being an attempt to satisfy the heightened tolerance
to opiates by taking a range of substances providing an alternative re-
warding effect (Maremmani and Shinderman, 1999). This possibility
is also supported by the positive outcomes achieved when AOTs with
over-standard dosages are adopted (Peles et al., 2005, 2006). Another
assumption, although not mutually exclusive with the previous one,
considers the subsequent use of cocaine in FHA patients as an attempt
to augment or optimize the baseline energy level and resolve the hypo-
phoria derived from the long-term use of heroin (and other sedatives)
(Maremmani et al., 2008).
In the present study, FHA-AUD patients showed a greater num-
ber of alcohol units per day and reached a higher maximum con-
sumption of alcohol than NFHA-AUD patients at the beginning of
AUD. An observation of this kind was first made by Ceccanti and
Vitali (Ceccanti and Vitali, 2009). One possible explanation for
greater alcohol consumption in FHA-AUD patients is related to the
need for a cross-acting substance (alcohol specifically, but benzodia-
zepines could be involved as well) to compensate for the lack of
heroin/opioid availability (Maremmani and Shinderman, 1999).
Indeed, patients treated with low dosages of methadone show a
stronger craving alcohol as well as for heroin (Lubrano et al.,
2002). We observed the need for high doses of methadone in
heroin-addicted patients who are prone to concomitant alcohol or
benzodiazepine abuse (Maremmani et al., 2007).
Looking nowat the heroin dependence history of our sample, more
than two-thirds of our sample reached the latest stage of heroin de-
pendence (the ‘revolving door’ phase). In spite of this, only one-third
had ever enrolled in an AOT programme and, of these, slightly more
than half reached blocking dosages. As previously mentioned, reach-
ing blocking dosage and long-term staying in treatment (but also,
performing all the phases of treatment—induction, stabilization,
maintenance and reduction of medication under medical supervision)
are critical to the success of an AOT programme (Dole, 1999;
Maremmani et al., 2003b, 2011; Fareed et al., 2009; Maremmani
and Pacini, 2009a,b; Pacini et al., 2010a). Unfortunately, dosages
below recommended levels have been highlighted in one-third of
methadone facilities in the USA (Pollack and D’Aunno, 2008). It
appears that our FHA-AUD patients often had not received an opti-
mized AOT programme, and ceased using heroin only to become an
AUD patients, so that an apparent remission was actually a switch
of addiction. Omitting or interrupting an effective treatment for
heroin dependence may favour substituting a surrogate. A premature
removal of agonist drugs, and the preference for drug-free regimens
are examples of interventions that may directly favour, or fail to
Table 3. Heroin dependence history of 60 former heroin-dependent
AUD patients at treatment entry
FHA-AUD patients
N = 60
Heroin dependence history
Age at continuous use of heroin (M ± SD)
(range)
22.12 ± 8.2 (13–49)
Stage 3 reacheda (N (%)) 53 (88.3)
Heroin dependence length (M ± SD) (range) in
years
9.38 ± 5.5 (1–21)
Age when heroin use stopped (N (%)) 34.09 ± 7.2 (26–48)
Heroin free for almost 2 years (N (%)) 36 (60.0)
Treatment history
Age at alcohol treatment request (M ± SD)
(range)
43.38 ± 6.3 (22–58)
Past opioid agonist treatment (N (%)) 18 (30.5)
AOT length (in years) (M ± SD) (range) 5.30 ± 4.0 (1–12)
Age at last AOT (in years) (M ± SD) (range) 33.92 ± 8.1 (25–50)
Blocking doses (at least 80 mg of methadone and
16 mg of buprenorphine) not reached (N (%))
34 (56.6)
aStage 3 is defined as the ‘revolving door phase’ of heroin dependence, which
identifies the last stage of the illness.
Table 2.Most significant correlates of 60 former users of heroin from
among 448 AUD patients applying for treatment
Predictors Step Odds
ratio
Min Max P
Age 3 1.05 1.01 1.08 0.006
Concomitant use of cocaine 2 5.70 2.64 12.33 0.000
Concomitant use of
cannabinoids
1 4.97 2.36 10.46 0.000
Statistics: chi-square =75.01, df = 3, P < 001; correctly classified: 90.0%.
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counter, a switching evolution of heroin dependence towards
alcoholism (Pacini et al., 2005).
The prevalence of alcohol use during AOT is put at about
one-third (Chen et al., 2011), though ranging from 5 to 50%
(Rittmannsberger et al., 2000; Backmund et al., 2003). Nevertheless,
there are few studies of emerging alcohol use in former heroin-
dependent patients, despite the consensus that a percentage of heroin-
dependent patients can develop alcoholism or serious drinking
problems heroin addiction (Simpson and Sells, 1974; Belenko, 1979;
Rounsaville et al., 1982; Lehman et al., 1990; Ottomanelli, 1999;
Gossop et al., 2006; Ryder et al., 2009; Blagov and Kurgak, 2011).
A connection between alcohol and opiate receptors is recognized
(Gianoulakis, 1993; Froehlich and Li, 1994; Gianoulakis and de
Waele, 1994; Gianoulakis et al., 1996; Herz, 1997), and naltrexone
and nalmefene have been approved for the treatment of alcoholism;
they take advantage of antagonist action on opioid mu-receptors,
which in its turn has the effect of reducing the alcohol reward effect
(Volpicelli et al., 1995; Rosner et al., 2010; Hillemacher, 2011).
At present, there is a lack of apparent interest in agonist opioid
medications, despite the fact that the literature shows that encouraging
results in the treatment of specific behaviour patterns in populations of
AUD patients have been reported after treatment with agonist opioids.
Regarding AUD treatment during AOT, both methadone and bupre-
norphine were able to reduce alcohol use, but greater effectiveness
was found with higher doses of buprenorphine compared with higher
doses of methadone (32 and 200 mg/day, respectively) (Nava et al.,
2008). Overall, high doses of methadone (over 100 mg/day) have
been previously appeared necessary to reduce abuse of alcohol
(Maxwell and Shinderman, 1999). In line with these findings, metha-
done dosage was correlated with craving for alcohol in heroin-
dependent patients; patients treated with low dosages of methadone
showing stronger cravings for both heroin and alcohol (Lubrano
et al., 2002). In addition, the prevalence of alcohol in naltrexone main-
tained heroin-dependent patients is quite high (Maremmani et al.,
2003a). In a sample of non-alcoholic heroin-addicted patients, short-
termmethadone administration was associated with alcohol reduction,
though individual cases required the dosage of the opioid to be raised
to very high levels (methadone, for instance, to 400 mg daily) (Caputo
et al., 2002).
Dihydrocodeine and buprenorphine have shown promising results
in AUD patients without any previous use of opiates (Ulmer et al.,
2007, 2009, 2012). Anecdotally, we too found low-dose buprenor-
phine to be effective in treating former heroin-dependent AUD
patients (Piz et al., 2011; Maremmani et al., 2014).
CONCLUSIONS
The prevalence of FHA-AUD patients is not negligible. This specific
cluster of AUD patients, not alcohol-dependent during heroin use,
seems to have been inadequately treated for their heroin dependence,
and tends to develop a more severe form of AUD. For these patients we
propose a reconsideration of low dose or ‘soft’ AOT as therapy worth
further investigation.
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